• Publications
  • Influence
Evaluation of the cyclooxygenase selectivity of robenacoxib and its effect on recovery of ischemia-injured jejunal mucosa in horses.
Robenacoxib selectively inhibited COX-2 and allowed recovery of barrier function in ischemia-injured equine jejunal tissue in vitro.
The effects of a novel anti-inflammatory compound (AHI-805) on cyclooxygenase enzymes and the recovery of ischaemia injured equine jejunum ex vivo.
Flunixin meglumine and AHI-805 inhibit recovery of barrier function in ischaemic-injured equine jejunum in vitro through inhibition of the COX enzymes.
The cyclooxygenase selectivity and effect of robenacoxib on the recovery of ischemic-injured equine jejunum ex vivo
Robenacoxib selectively inhibits COX-2 and allows recovery of barrier function in ischemic-injured equine jejunum in-vitro and there was a significant increase in PGEM and TXB2 in control and robenacxib-treated tissues but not flunixin meglumine- treated tissues.
Effects of the novel anti‐inflammatory drugs robenacoxib and AHI‐805 on recovery of ischemic injured equine jejunum ex vivo
Robenacoxib permits recovery of ischemic‐injured jejunum judging by indices of barrier function, and this is linked to its ability to allow enhanced PG production.